BHVN - BIOHAVN PHRMCTCL （）

Biohaven press release (BHVN): Q4 Non-GAAP EPS of -$1.27 beats by $0.01.Cash, cash equivalents and marketable securities as of December 31, 2022 was $465.3 million, excluding…

Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global (ex-China) rights; Phase 1 clinical trial initiation anticipated in 2023 Completed Phase 1 SAD/MAD study with BHV-7000 from our Kv7 ion channel…

Biohaven (BHVN) said it acquired global rights, excluding China regions, for BHV-8000 to treat brain disorders from Hangzhou Highlightll Pharmaceutical.Highlightll will get…

https://www.investing.com/news/pro/biohaven-pharma-acquires-exclusive-license-for-oral-brainpenetrant-dual-tyk2jak1-inhibitor-for-immunemediated-brain-disorders-432SI-3036600

Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitors Exclusive license covers global rights excluding China…

A share of Biohaven Ltd. (NYSE:BHVN) closed at $18.08 per share on Monday, down from $18.19 day before. While Biohaven Ltd. has underperformed by -0.60%, investors are advised to look at stock chart patterns for technical insight. On January 24, 2023, SVB Securities started tracking Biohaven Ltd. (NYSE: BHVN) recommending Outperform. A report published by […]

Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared.

Pfizer on Tuesday, January 31, forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and treatment for 2023, intensifying investor concerns over demand for the products as governments cut orders and work through inventories. Chief executive Albert Bourla said that 2023 should be a “transition year” for Pfizer’s COVID products, before potentially returning to growth in 2024. Pfizer’s total annual sales crossed the $100-billion mark for the first time in 2022, driven by the more than $56 billion in sales of its COVID-19 vaccine and Paxlovid antiviral treatment. It expects total 2023 revenue of $67 billion to $71 billion. “We are building on a significant capital position that we know how to deploy to create growth,” Bourla told analysts and investors on conference call. “We are building an R&D engine that is more productive than ever.” The company launched five new products last year and hopes to introduce as many as 14 more over the next year and a half, including a vaccine for respiratory syncytial virus (RSV) and an mRNA flu vaccine.

Related Stocks: AERI , BHVN , DOCS , OABI , RXO ,

Related Stocks: CHNG , ACI , CLM , STAR , BHVN ,

By Manas Mishra (Reuters) -Pfizer Inc on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations. The U.S. drugmaker''s shares rose 2.4% to $447.67 in morning trading as its third-quarter profit beat estimates, mainly due to better-than-expected sales of the vaccine. The upbeat earnings also sent shares of rival COVID-19 vaccine makers higher. Novavax Inc rose 11%, while Moderna Inc gained about 4%. Sales of the COVID-19 vaccine have eased from pandemic highs on soft demand for the original shots, sparking concerns over demand over the next few years. In response, Pfizer plans to roughly quadruple the price of the vaccine, which it sells with German partner BioNTech, in the United States once the government stops buying doses and shifts to a private market. "Our COVID-19 franchises will remain multi-billion-dollar revenue generators for the foreseeable future," Chief Executive Officer Albert Bourla said in prepared remarks ahead of a conference call.

https://www.investing.com/news/pro/biohaven-pharma-ceo-buys-another-400k-in-stock-432SI-2928059

Biohaven Ltd. (NYSE:BHVN) closed Friday at $15.33 per share, up from $13.83 a day earlier. While Biohaven Ltd. has overperformed by 10.85%, investors are advised to look at stock chart patterns for technical insight. On October 26, 2022, Cantor Fitzgerald Upgraded Biohaven Ltd. (NYSE: BHVN) to Overweight. A report published by Piper Sandler on October […]

Matthew Buten , Chief Financial Officer at Biohaven (NYSE: BHVN ), reported a large insider buy on October 26, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Buten purchased 142,857 shares of Biohaven. The total transaction amounted to $1,499,998. Biohaven shares are trading up 1.25% at $13.78 at the time of this writing on Thursday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used primarily to make … Full story available on Benzinga.com

Vlad Coric , Chief Executive Officer at Biohaven (NYSE: BHVN ), reported a large insider buy on October 26, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Coric purchased 853,380 shares of Biohaven. The total transaction amounted to $8,960,490. Biohaven shares are trading up 1.25% at $13.78 at the time of this writing on Thursday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used primarily to make … Full story available on Benzinga.com